ストックスクリーナーアプリを入手
1.64
3.81%
0.04
前日終値:
$1.60
開ける：
$1.61
24時間の取引高:
324.17K
Relative Volume:
0.26
時価総額：
$103.73M
収益：
-
当期純損益:
$-131.52M
株価収益率:
-0.9213
EPS:
-1.78
ネットキャッシュフロー:
$-107.56M
1週間 パフォーマンス:
+9.28%
1か月 パフォーマンス:
+1.28%
6か月 パフォーマンス:
+81.71%
1年 パフォーマンス:
+71.73%
1日の値動き範囲:
$1.5201
$1.69
1週間の範囲:
$1.46
$1.73
52週間の値動き範囲:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
名前
Prelude Therapeutics Inc
セクター
電話
(302) 467-1280
住所
175 INNOVATION BOULEVARD, WILMINGTON
PRLD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.65 | 100.58M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.11 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
760.62 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
437.90 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
921.89 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
200.18 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-02-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 開始されました | Jefferies | Buy |
| 2022-03-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-02-28 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-10-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-04-26 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2020-11-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-10-20 | 開始されました | Goldman | Neutral |
| 2020-10-20 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prelude Therapeutics Inc (PRLD) 最新ニュース
Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends - Markets Mojo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics IncorporatedPRLD - PR Newswire
Will Prelude Therapeutics Incorporated stock outperform Dow Jones indexJuly 2025 Sentiment & Smart Money Movement Alerts - newser.com
Is Prelude Therapeutics Incorporated stock supported by innovation pipeline2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation ... - Bakersfield.com
PRLD Investors Have Opportunity to Join Prelude - GlobeNewswire
What to do if you’re stuck in Prelude Therapeutics IncorporatedPortfolio Update Summary & Smart Investment Allocation Insights - newser.com
Is Prelude Therapeutics Incorporated stock ready for a breakoutJuly 2025 Sector Moves & Weekly Market Pulse Updates - newser.com
What sentiment indicators say about Prelude Therapeutics Incorporated stock2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 - MyChesCo
Order flow analysis tools used on Prelude Therapeutics IncorporatedJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com
Can Prelude Therapeutics Incorporated stock hit analyst price targets2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
Real time alert setup for Prelude Therapeutics Incorporated performanceProduct Launch & Safe Entry Trade Signal Reports - newser.com
Is Prelude Therapeutics Incorporated stock supported by strong fundamentalsJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
Using flow based indicators on Prelude Therapeutics Incorporated2025 Market Sentiment & Fast Moving Trade Plans - newser.com
Taking on analysts’ expectations and winning: Prelude Therapeutics Inc (PRLD) - Setenews
Prelude Therapeutics’ Earnings Call Highlights Strategic Moves and Challenges - MSN
Published on: 2025-11-16 22:10:23 - newser.com
What institutional flow reveals about Prelude Therapeutics IncorporatedJuly 2025 Earnings & Safe Capital Growth Tips - newser.com
Is Prelude Therapeutics Incorporated stock a defensive play in 2025Weekly Risk Summary & Daily Oversold Bounce Ideas - newser.com
How to build a custom watchlist for Prelude Therapeutics IncorporatedJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
Pattern recognition hints at Prelude Therapeutics Incorporated upsideSwing Trade & Advanced Technical Analysis Signals - newser.com
How moving averages guide Prelude Therapeutics Incorporated tradingBuy Signal & Weekly Breakout Watchlists - newser.com
Can Prelude Therapeutics Incorporated stock sustain free cash flow growthJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Volume spikes in Prelude Therapeutics Incorporated stock – what they meanMarket Performance Report & Daily Stock Momentum Reports - newser.com
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Q3 2025 Earnings Call Transcript - Insider Monkey
Will Prelude Therapeutics Incorporated stock deliver shareholder valueTrade Exit Summary & AI Forecast for Swing Trade Picks - newser.com
Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Published on: 2025-11-14 02:04:28 - newser.com
MSN Money - MSN
Prelude Therapeutics Advances Pipeline and Strengthens Financials - TipRanks
Transcript : Prelude Therapeutics Incorporated, Q3 2025 Earnings Call, Nov 12, 2025 - MarketScreener
Can Prelude Therapeutics Incorporated stock maintain operating margins2025 Key Lessons & Expert Approved Momentum Trade Ideas - newser.com
Prelude Therapeutics Inc (PRLD) Q3 2025 Earnings Call Highlights - GuruFocus
Prelude Therapeutics Inc (PRLD) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Earnings call transcript: Prelude Therapeutics Q3 2025 sees stock steadiness By Investing.com - Investing.com South Africa
Earnings call transcript: Prelude Therapeutics Q3 2025 sees stock steadiness - Investing.com India
Prelude Therapeutics Inc (PRLD) 財務データ
収益
当期純利益
現金流量
EPS
Prelude Therapeutics Inc (PRLD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
1.64%
0.70%
大文字化:
|
ボリューム (24 時間):